IQVIA Holdings Inc. reported a revenue increase of 8.4% for the first quarter of 2026, reaching $4.151 billion compared to $3.829 billion in the same period of 2025. The company's net income also rose to $275 million, or $1.63 per share, up from $249 million, or $1.42 per share, in the prior year. This growth in revenue and profitability was attributed to strong performance in both the Commercial Solutions and Research & Development Solutions segments, which saw increases of 11.6% and 6.2%, respectively.
The company's cost of revenues increased to $2.796 billion from $2.531 billion, reflecting a rise in operational expenses associated with service delivery. Selling, general, and administrative expenses decreased slightly to $502 million from $508 million, indicating improved efficiency. The increase in costs was primarily driven by higher compensation and related expenses, which were necessary to support the growing demand for IQVIA's services. Additionally, restructuring costs rose to $51 million from $29 million as the company continued to streamline operations and integrate recent acquisitions.
In terms of strategic developments, IQVIA completed several immaterial acquisitions during the quarter, contributing to its growth strategy. The company also reorganized its reportable segments, merging the Contract Sales & Medical Solutions segment into the newly named Commercial Solutions segment. This restructuring aims to align operational activities more closely with market demands and improve service delivery. As of March 31, 2026, IQVIA employed approximately 93,000 individuals across more than 100 countries, maintaining a strong workforce to support its global operations.
Operationally, IQVIA's backlog in the Research & Development Solutions segment increased to $34.2 billion, with expectations of approximately $8.9 billion converting to revenue within the next twelve months. The company reported a decrease in cash and cash equivalents to $1.947 billion from $1.980 billion at the end of 2025, while net cash provided by operating activities increased to $618 million from $568 million. This positive cash flow reflects the company's ability to generate cash from its operations, which is crucial for funding future growth initiatives.
Looking ahead, IQVIA remains optimistic about its growth trajectory, supported by a strong pipeline of services and a commitment to leveraging advanced analytics and technology. The company anticipates continued revenue growth driven by its strategic focus on enhancing service offerings and expanding its market presence. However, management acknowledges potential risks, including market fluctuations and regulatory changes, which could impact future performance.
About IQVIA HOLDINGS INC.
IQVIA is a global provider of healthcare data, analytics, and technology solutions serving the life sciences and healthcare industries. It offers clinical research services, real-world evidence, commercial insights, and AI-powered platforms to optimize drug development, clinical trials, and healthcare operations. With extensive proprietary data and a broad client base, IQVIA supports innovation, regulatory compliance, and improved patient outcomes worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.